Does the media favor DYAI or ARCT?

In the previous week, Arcturus Therapeutics had 3 more articles in the media than Dyadic International. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 2 mentions for Dyadic International. Arcturus Therapeutics' average media sentiment score of 0.39 beat Dyadic International's score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcturus Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to OKUR or DYAI?

In the previous week, OnKure Therapeutics had 3 more articles in the media than Dyadic International. MarketBeat recorded 5 mentions for OnKure Therapeutics and 2 mentions for Dyadic International. OnKure Therapeutics' average media sentiment score of 1.13 beat Dyadic International's score of 0.00 indicating that OnKure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DYAI or LFCR?

In the previous week, Lifecore Biomedical had 9 more articles in the media than Dyadic International. MarketBeat recorded 11 mentions for Lifecore Biomedical and 2 mentions for Dyadic International. Lifecore Biomedical's average media sentiment score of 0.61 beat Dyadic International's score of 0.00 indicating that Lifecore Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lifecore Biomedical 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MOLN or DYAI?

In the previous week, Dyadic International had 1 more articles in the media than Molecular Partners. MarketBeat recorded 2 mentions for Dyadic International and 1 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.75 beat Dyadic International's score of 0.00 indicating that Molecular Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Molecular Partners 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NKTX or DYAI?

In the previous week, Nkarta had 1 more articles in the media than Dyadic International. MarketBeat recorded 3 mentions for Nkarta and 2 mentions for Dyadic International. Nkarta's average media sentiment score of 0.45 beat Dyadic International's score of 0.00 indicating that Nkarta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Dyadic International (DYAI) Competitors

$0.97 -0.11 (-10.23%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$1.01 +0.04 (+4.18%)

As of 08/5/2026 07:55 PM Eastern

Compare

DYAI vs. ARCT, OKUR, LFCR, MOLN, and NKTX

Should you buy Dyadic International stock or one of its competitors? MarketBeat compares Dyadic International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dyadic International include Arcturus Therapeutics (ARCT), OnKure Therapeutics (OKUR), Lifecore Biomedical (LFCR), Molecular Partners (MOLN), and Nkarta (NKTX).

How does Dyadic International compare to Arcturus Therapeutics?

Dyadic International (NASDAQ:DYAI) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Dyadic International currently has a consensus price target of $3.00, indicating a potential upside of 209.44%. Arcturus Therapeutics has a consensus price target of $24.25, indicating a potential upside of 287.38%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Arcturus Therapeutics has a net margin of -143.80% compared to Dyadic International's net margin of -192.40%. Arcturus Therapeutics' return on equity of -36.55% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-192.40%	-1,005.45%	-77.64%
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%

Dyadic International has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.39, indicating that its share price is 139% more volatile than the broader market.

In the previous week, Arcturus Therapeutics had 3 more articles in the media than Dyadic International. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 2 mentions for Dyadic International. Arcturus Therapeutics' average media sentiment score of 0.39 beat Dyadic International's score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcturus Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Dyadic International has higher earnings, but lower revenue than Arcturus Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	11.43	-$7.36M	-$0.23	N/A
Arcturus Therapeutics	$82.03M	2.17	-$65.78M	-$2.81	N/A

Summary

Arcturus Therapeutics beats Dyadic International on 13 of the 17 factors compared between the two stocks.

How does Dyadic International compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

In the previous week, OnKure Therapeutics had 3 more articles in the media than Dyadic International. MarketBeat recorded 5 mentions for OnKure Therapeutics and 2 mentions for Dyadic International. OnKure Therapeutics' average media sentiment score of 1.13 beat Dyadic International's score of 0.00 indicating that OnKure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OnKure Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 404.81%. Dyadic International has a consensus price target of $3.00, indicating a potential upside of 209.44%. Given OnKure Therapeutics' higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 2.2% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 20.9% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dyadic International has higher revenue and earnings than OnKure Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
Dyadic International	$3.09M	11.43	-$7.36M	-$0.23	N/A

OnKure Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. OnKure Therapeutics' return on equity of -57.37% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-57.37%	-52.78%
Dyadic International	-192.40%	-1,005.45%	-77.64%

OnKure Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Dyadic International has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

Summary

OnKure Therapeutics beats Dyadic International on 8 of the 15 factors compared between the two stocks.

How does Dyadic International compare to Lifecore Biomedical?

Dyadic International (NASDAQ:DYAI) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dyadic International has higher earnings, but lower revenue than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	11.43	-$7.36M	-$0.23	N/A
Lifecore Biomedical	$128.87M	1.29	-$35.26M	-$0.94	N/A

Dyadic International presently has a consensus price target of $3.00, indicating a potential upside of 209.44%. Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 46.40%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts clearly believe Dyadic International is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lifecore Biomedical has a net margin of -25.43% compared to Dyadic International's net margin of -192.40%. Lifecore Biomedical's return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-192.40%	-1,005.45%	-77.64%
Lifecore Biomedical	-25.43%	N/A	-14.40%

In the previous week, Lifecore Biomedical had 9 more articles in the media than Dyadic International. MarketBeat recorded 11 mentions for Lifecore Biomedical and 2 mentions for Dyadic International. Lifecore Biomedical's average media sentiment score of 0.61 beat Dyadic International's score of 0.00 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifecore Biomedical	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dyadic International has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Summary

Dyadic International and Lifecore Biomedical tied by winning 8 of the 16 factors compared between the two stocks.

How does Dyadic International compare to Molecular Partners?

Molecular Partners (NASDAQ:MOLN) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

In the previous week, Dyadic International had 1 more articles in the media than Molecular Partners. MarketBeat recorded 2 mentions for Dyadic International and 1 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.75 beat Dyadic International's score of 0.00 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Molecular Partners currently has a consensus price target of $8.38, suggesting a potential upside of 109.90%. Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 209.44%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Dyadic International has lower revenue, but higher earnings than Molecular Partners. Dyadic International is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	28.52	-$74.41M	-$1.94	N/A
Dyadic International	$3.09M	11.43	-$7.36M	-$0.23	N/A

Molecular Partners has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Comparatively, 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Molecular Partners has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Molecular Partners' return on equity of -66.62% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Summary

Dyadic International beats Molecular Partners on 8 of the 15 factors compared between the two stocks.

How does Dyadic International compare to Nkarta?

Nkarta (NASDAQ:NKTX) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Nkarta currently has a consensus price target of $10.75, indicating a potential upside of 388.64%. Dyadic International has a consensus price target of $3.00, indicating a potential upside of 209.44%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Nkarta has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Dyadic International has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

In the previous week, Nkarta had 1 more articles in the media than Dyadic International. MarketBeat recorded 3 mentions for Nkarta and 2 mentions for Dyadic International. Nkarta's average media sentiment score of 0.45 beat Dyadic International's score of 0.00 indicating that Nkarta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.5% of Nkarta shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 9.8% of Nkarta shares are held by company insiders. Comparatively, 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dyadic International has higher revenue and earnings than Nkarta. Dyadic International is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Dyadic International	$3.09M	11.43	-$7.36M	-$0.23	N/A

Nkarta has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Nkarta's return on equity of -30.90% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Summary

Nkarta beats Dyadic International on 11 of the 16 factors compared between the two stocks.

Get Dyadic International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYAI vs. The Competition

Export

Metric	Dyadic International	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$39.35M	$3.57B	$6.87B	$12.98B
Dividend Yield	N/A	3.76%	2.60%	9.79%
P/E Ratio	-4.22	7.68	280.35	25.27
Price / Sales	11.43	1,310.50	604.17	94.27
Price / Cash	N/A	103.01	71.79	50.79
Price / Book	32.32	17.16	12.97	6.09
Net Income	-$7.36M	-$12.52M	$3.49B	$347.95M
7 Day Performance	-9.39%	2.34%	2.41%	3.11%
1 Month Performance	0.20%	-5.11%	-2.87%	-2.99%
1 Year Performance	-1.59%	52.15%	75.28%	20.51%

Dyadic International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYAI Dyadic International	2.625 of 5 stars	$0.97 -10.2%	$3.00 +209.4%	-1.1%	$39.35M	$3.09M	N/A	7	Upcoming Earnings High Trading Volume
ARCT Arcturus Therapeutics	2.313 of 5 stars	$5.75 -0.2%	$24.25 +321.7%	-47.1%	$163.72M	$42.35M	N/A	180	Positive News Upcoming Earnings
OKUR OnKure Therapeutics	3.0242 of 5 stars	$3.95 -2.5%	$21.00 +431.6%	+92.6%	$163.60M	N/A	N/A	N/A	Positive News Earnings Report Upcoming Earnings
LFCR Lifecore Biomedical	1.7826 of 5 stars	$4.39 +1.2%	$6.50 +48.1%	-38.8%	$162.79M	$128.87M	N/A	690	Trending News Earnings Report
MOLN Molecular Partners	2.4689 of 5 stars	$3.77 -6.0%	$8.38 +122.1%	+8.8%	$161.70M	$5.65M	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYAI) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyadic International (DYAI) Competitors

DYAI vs. ARCT, OKUR, LFCR, MOLN, and NKTX

How does Dyadic International compare to Arcturus Therapeutics?

Summary

How does Dyadic International compare to OnKure Therapeutics?

Summary

How does Dyadic International compare to Lifecore Biomedical?

Summary

How does Dyadic International compare to Molecular Partners?

Summary

How does Dyadic International compare to Nkarta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyadic International (DYAI) Competitors

DYAI vs. ARCT, OKUR, LFCR, MOLN, and NKTX

How does Dyadic International compare to Arcturus Therapeutics?

Do analysts recommend DYAI or ARCT?

Is DYAI or ARCT more profitable?

Which has more risk & volatility, DYAI or ARCT?

Does the media favor DYAI or ARCT?

Do institutionals and insiders have more ownership in DYAI or ARCT?

Which has stronger earnings & valuation, DYAI or ARCT?

Summary

How does Dyadic International compare to OnKure Therapeutics?

Does the media refer more to OKUR or DYAI?

Do analysts recommend OKUR or DYAI?

Do insiders and institutionals have more ownership in OKUR or DYAI?

Which has preferable valuation and earnings, OKUR or DYAI?

Is OKUR or DYAI more profitable?

Which has more risk & volatility, OKUR or DYAI?

Summary

How does Dyadic International compare to Lifecore Biomedical?

Do insiders & institutionals have more ownership in DYAI or LFCR?

Which has preferable earnings and valuation, DYAI or LFCR?

Do analysts rate DYAI or LFCR?

Is DYAI or LFCR more profitable?

Does the media favor DYAI or LFCR?

Which has more risk & volatility, DYAI or LFCR?

Summary

How does Dyadic International compare to Molecular Partners?

Does the media refer more to MOLN or DYAI?

Do analysts recommend MOLN or DYAI?

Which has higher valuation and earnings, MOLN or DYAI?

Which has more volatility and risk, MOLN or DYAI?

Do insiders & institutionals hold more shares of MOLN or DYAI?

Is MOLN or DYAI more profitable?

Summary

How does Dyadic International compare to Nkarta?

Do analysts prefer NKTX or DYAI?

Which has more volatility and risk, NKTX or DYAI?

Does the media refer more to NKTX or DYAI?

Do institutionals and insiders believe in NKTX or DYAI?

Which has higher earnings and valuation, NKTX or DYAI?

Is NKTX or DYAI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools